Rapamycin and Longevity

Attia: The 2014 everolimus immunity study as the turning point for human rapamycin use

Andrew Huberman

“The 2014 Joan Mannick and Lloyd Klickstein study using everolimus in elderly subjects was a pivotal moment that shifted rapamycin from a mouse-only curiosity to a serious human longevity candidate. Unlike daily immunosuppressive dosing used in organ transplant patients, intermittent low-dose rapamycin analogs were shown to enhance immune response to influenza vaccine in older adults. This finding, combined with the 2009 ITP mouse lifespan data, provided a human proof-of-concept that mTOR inhibition could offer longevity and immune benefits at the right dose and schedule.”

Sabbatini/Attia: Prolonged rapamycin exposure inhibits mTORC2 by preventing Rictor complex assembly

Peter Attia

“Prolonged rapamycin exposure inhibits not only mTORC1 but also mTORC2, through a mechanism where FKBP-rapamycin binds to nascent 'naked' mTOR before Rictor can associate, preventing mTORC2 assembly entirely. This chronic inhibition of mTORC2 leads to suppression of Akt signaling, an effect not seen with short-term rapamycin treatment. This discovery, initially met with skepticism, has important implications for understanding rapamycin's broader biological effects relevant to longevity research.”

Judith: mTOR dampening via fasting or rapamycin extends lifespan across species

Rhonda Patrick

“mTOR is a highly conserved nutrient- and growth factor-sensing kinase whose activity scales with nutrient availability. Dampening mTOR activity — either genetically or pharmacologically with rapamycin — extends lifespan in yeast, worms, flies, and mice. Fasting may achieve similar benefits partly by suppressing mTOR activity, potentially explaining how it reduces chemotherapy side effects and improves cancer treatment efficacy.”

Attia/Huberman: Rapamycin as the single best example of a geroprotective molecule

Andrew Huberman

“Rapamycin is categorized as a geroprotective agent—distinct from disease-specific treatments—because it directly targets core hallmarks of aging, particularly the mTOR nutrient-sensing pathway. Among exogenous molecules proposed to extend lifespan, it is argued to be the single best example, supported by experimental evidence linking mTOR inhibition to increased longevity.”

Attia: ITP mouse studies and rapamycin's 15% lifespan extension

Peter Attia

“The Interventions Testing Program (ITP), an NIH-funded, multi- site study using genetically diverse mice, demonstrated in 2009 that rapamycin extended lifespan by roughly 15% even when administration began very late in life (20 months, equivalent to old age). The ITP is considered the gold standard for preclinical longevity research due to its rigorous design, large sample sizes, and concurrent replication across three independent labs. No equivalent randomized controlled trial exists in humans, making it impossible to draw definitive conclusions about rapamycin's longevity effects in people, a gap that remains a central limitation of the field.”

Attia: Rapamycin lacks commercial interest but drives scientific research

Andrew Huberman

“Rapamycin is an off-patent drug with no major commercial backing, making it approximately $5 per milligram (roughly $40/week at longevity dosing), yet this lack of profit motive may actually support more objective scientific research. Commercial interest has instead shifted toward rapalogs—rapamycin analogues being developed by companies for new indications such as immune function.”

Attia/Kay: chronic vs transient rapamycin dosing and longevity outcomes

Peter Attia

“FKBP-rapamycin complex inhibits mTORC2 by preventing the interaction between mTOR and its binding partner Rictor. Despite this mechanistic complexity, ITP studies using constitutive rapamycin dosing still demonstrate longevity benefits, suggesting the network-level effects of chronic versus transient rapamycin treatment are not fully explained by current biochemical models. The longevity outcomes were observed before the underlying mechanisms were well understood, meaning researchers are now working backwards to reconcile the biology.”

Attia/Baker: Why chronic rapamycin dosing still extends lifespan despite mTORC2 inhibition concerns

Peter Attia

“Although rapamycin's mechanism involves preventing mTOR and Raptor complex formation (mTORC1 inhibition) while potentially also disrupting mTORC2, the longevity benefits observed in ITP and other studies preceded full mechanistic understanding. The complexity of the mTOR signaling network means that the downstream effects of transient versus chronic rapamycin dosing at various doses are difficult to predict from biochemical first principles alone, and researchers are now working backward from observed longevity outcomes to explain the mechanisms rather than the other way around.”

Attia: Rapamycin's journey from transplant drug to longevity breakthrough

Peter Attia

“Rapamycin, originally approved by the FDA in 1999 as an immunosuppressant for organ transplantation, gained landmark significance in longevity research when a 2009 Interventions Testing Program study demonstrated it extended lifespan in both male and female mice — crucially, even when administered late in life, something no other drug had achieved. This finding was replicated across multiple studies and model organisms spanning roughly a billion years of evolution, including yeast, fruit flies, and worms, all pointing to mTOR inhibition as a conserved longevity mechanism.”

Attia: Personal rapamycin protocol and side effects

Andrew Huberman

“Rapamycin is taken at 8mg once weekly as a geroprotective intervention based on its believed capacity for longevity extension. Approximately 10% of users experience aphthous ulcers (canker sores) as a side effect, necessitating periodic breaks from the regimen. The drug is distinguished from disease- specific medications as a broadly aging-targeted molecule, alongside SGLT2 inhibitors like canagliflozin which have shown geroprotective effects in the Interventions Testing Program.”

Attia: Personal rapamycin dosing protocol and conviction based on experimental data

Andrew Huberman

“Peter Attia takes 8mg of rapamycin once weekly, cycling roughly two months on and one month off due to canker sore side effects that affect ~10% of users. He views rapamycin's longevity benefits as grounded primarily in experimental data rather than mechanistic arguments alone, though mTOR inhibition's role in stimulating autophagy and suppressing senescent cells provides a compelling theoretical framework.”

Attia: Rapamycin as cancer preventive vs. chemotherapeutic agent

Peter Attia

“Rapamycin inhibits mTOR and slows biological aging, making it a promising preventive agent against cancer. However, as a chemotherapeutic drug it often fails because cancers evolve to bypass mTOR inhibition. This distinction illustrates that the biology of aging operates as a network of nodes—manipulating mTOR prophylactically is fundamentally different from using it to treat established disease—and that traditional disease-based medicine fails to appreciate this difference.”

Attia: ITP uses daily low-dose rapamycin in mice, contrasting with intermittent human dosing regimens

Peter Attia

“The Interventions Testing Program (ITP) administers rapamycin continuously by mixing it into mouse chow at low doses, allowing mice to consume it throughout the day. This differs substantially from the intermittent dosing regimens being explored in companion dogs and humans. Understanding how intermittent dosing compares to continuous daily dosing in the same ITP mouse model would be a valuable and relatively affordable research question to answer.”

Attia: Rapamycin as cancer preventive vs. chemotherapeutic agent

Peter Attia

“Rapamycin inhibits mTOR and is believed to slow biological aging, but fails as a chemotherapeutic agent because cancers evolve to bypass mTOR inhibition. Paradoxically, this same mechanism makes rapamycin potentially effective as a cancer preventive agent rather than a treatment. This distinction illustrates why aging biology requires a fundamentally different investigative framework than traditional disease-based medicine.”

Attia: rapamycin's origins and its promise for longevity

Peter Attia

“Rapamycin is a molecule discovered from a bacterium (Streptomyces hygroscopicus) found on Easter Island in the mid-1960s, named after the island's indigenous name, Rapa Nui. Originally identified as a potent antifungal—likely evolved by the bacterium to combat fungi—it was initially explored as an antifungal drug before its broader biomedical significance was recognized. Peter Attia categorizes rapamycin as 'promising but not proven' for longevity, noting its extensive coverage elsewhere and directing listeners to prior deep-dive content.”

Attia & Patrick: mTOR complex biology and the balance between muscle maintenance and aging

Rhonda Patrick

“Rapamycin works by inhibiting mTOR (target of rapamycin), which forms two distinct complexes—mTORC1 and mTORC2—with tissue- specific activities. mTORC1 is essential for protein synthesis and muscle maintenance, meaning complete suppression leads to muscle wasting, while chronic overactivation promotes aging and age-related diseases like cancer. This balance illustrates why rapamycin's therapeutic potential lies in carefully modulated inhibition rather than complete suppression of the pathway.”

Supplements for Longevity & Their Efficacy | Dr. Peter Attia

Andrew Huberman

“rapamycin duh in an effort to essentially remove excess insulin blood glucose and thereby reduce mtor activity so essentially slow cellular growth and all that fits nicely into the logic that mtor is associated not just with development but with aging because”

Supplements for Longevity & Their Efficacy | Dr. Peter Attia

Andrew Huberman

“…ch was like wait a minute something's different if you take rapamycin as a human at least every day it seems to suppress your immune system but if you just pulse it once a week as they did in that study it seems to improve immune function which again means it'”

Gordon Lithgow, Ph.D. on Protein Aggregation, Iron Overload & the Search for Longevity Compounds

Rhonda Patrick

“…: Yeah. I mean, the mouse program has been very successful. Rapamycin was the drug that emerged as being robust and reproducible at all three sites where these experiments were conducted in mice. But a few years later, I guess it was a feeling that maybe we ca”

272 ‒ Rapamycin: potential longevity benefits, surge in popularity, unanswered questions, and more

Peter Attia

“…itional context to what David was saying which is that with rapamycin it's not only the drug but we also have genetic inhibition of mtor in each of those model systems that recapitulates the longevity and health span benefits so it's a rock solid airtight case”

369 ‒ Rethinking protein needs for muscle and longevity, and the benefits of creatine & sauna use

Peter Attia

“…uotient line. So they are punching well below their weight. And humans, we live 80 years. We should probably be 40 according to the data. By the way, we did live 40 years until modern medicine came along. So maybe we were totally on the curve correctly until m”

357 ‒ A new era of longevity science: models of aging, rapamycin trials, biological clocks, & more

Peter Attia

“…answer I can give you right now. Uh so if you had to guess and I'm hopeful that that the listeners are are with us because this idea of the >> the linear and monotonic increasing in damage is >> is the thing that has to be addressed if we're going to make a s”

Valter Longo, Ph.D. on Fasting-Mimicking Diet & Fasting for Longevity, Cancer & Multiple Sclerosis

Rhonda Patrick

“…ase pathway in aging 15 years ago. And we used to work with rapamycin back in the 90s, in the mid-90s, you know, while working with the cells from Mike Hall. But I always said that I never wanna work...I mean, not never, but I really am not enthusiastic workin”

357 ‒ A new era of longevity science: models of aging, rapamycin trials, biological clocks, & more

Peter Attia

“allows it to shine? And I'm actually not aware of literature that looked at uh rapammune or rapamy in isolation as a as a as a potential treatment for organ transplant patients. >> I I'm not either. At high enough doses, it may have that impact, but I think th”